Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06559644
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-05-14
Brief Title:
Hema-NeoTIL01 Cell Infusion Therapy in RelapsedRefractory Acute Leukemia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Assessment of the Safety and Efficacy of Hema-NeoTIL01 Cell Infusion Therapy in RelapsedRefractory Acute Leukemia A Single-Arm Open-Label Prospective Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial aims to investigate the safety optimal dosage and effectiveness of autologous tumor-specific T cells known as Hema-NeoTIL0 in treating relapsedrefractory B-ALLAML
Detailed Description:
Primary Objective
To assess the safety of Hema-NeoTIL01 in the treatment of relapsedrefractory acute leukemia B-ALLAML
Secondary Objective
To evaluate the efficacy of Hema-NeoTIL01 in relapsedrefractory acute leukemia B-ALLAML
To assess the safety of Hema-NeoTIL01 in the treatment of relapsedrefractory acute leukemia B-ALLAML
Secondary Objective
To evaluate the efficacy of Hema-NeoTIL01 in relapsedrefractory acute leukemia B-ALLAML
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None